In addition, we confirmed the role of mutated SF3B1 as a molecular biomarker of the MDS-RS subgroup [12,33], and we showed a correlation between the mutational status of SF3B1 and WT1 expression. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.